Therapy‐related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risksMalcolm A. Smith, Richard S. Ungerleider, Larry Rubinstein|Medical and Pediatric Oncology|1994Cited by 178
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, P. Mickey Williams et al.|JAMA Oncology|2020Cited by 106
Report of the Cancer Therapy Evaluation Program Monitoring Plan for Secondary Acute Myeloid Leukemia Following Treatment With EpipodophyllotoxinsMark Smith, E. A. Gehan, Larry Rubinstein et al.|JNCI Journal of the National Cancer Institute|1993Cited by 51
Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.Malcolm A. Smith, Richard H. Simon, Richard S. Ungerleider et al.|Journal of Clinical Oncology|1997Cited by 50
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Zihan Wei et al.|npj Precision Oncology|2022Cited by 42